EUVIMEDOpdag EUVIMED
Crossref

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer

Fabian Falkenbach iD, Francesco Di Bello, Natali Rodriguez Peñaranda, Mattia Longoni, Andrea Marmiroli, Quynh Chi Le, Zhe Tian, Jordan A Goyal iD, Nicola Longo, Salvatore Micali, Alberto Briganti, Ottavio De Cobelli and 6 more

The Prostate · 2025

DOI: 10.1002/pros.70045 ↗

At a glance

Journal article in The Prostate, 2025. Written by Fabian Falkenbach and 17 co-authors. Institution: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Major MEDLINE topics: Prostatic Neoplasms, Prostate-Specific Antigen, Early Detection of Cancer. 19 references. Funded by: The authors received no specific funding for this work..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The USPSTF recommendation against PSA screening (RAPS) in 2012 resulted in unfavorable changes in prostate cancer (PCa) outcomes. However, the effect on cancer‐specific mortality (CSM) in localized PCa has not been assessed.

Methods

Within the Surveillance, Epidemiology, and End Results database (2004–2021), we identified patients treated with radiotherapy (RT) or radical prostatectomy (RP) for localized PCa. Time trends were examined using least‐squares linear regression. Multivariable Cox regression was used to study the association between RAPS and PCa‐mortality.

Results

Of 270,092 patients aged < 75 years, 191,621 (70.1%) were treated before and 78,471 (29.1%) in the RAPS era. CSM at 6 years of follow‐up was 1.6% (95% confidence interval [CI]: 1.6, 1.7) before and 1.9% (95%CI: 1.8, 2.0) in the RAPS era ( p < 0.001). In multivariable Cox models adjusted to patient characteristics, RAPS era independently predicted 1.2‐fold higher CSM overall (95%CI: 1.1, 1.3; p < 0.001), 1.3‐fold higher CSM in RP‐patients (95%CI: 1.1, 1.4; p < 0.001), and 1.1‐fold higher CSM in RT‐patients (95%CI: 1.02, 1.2; p = 0.02) aged < 75 years. Of 33,688 patients aged ≥ 75 years, 12,485 (37.1%) were treated before and 21,203 (62.9%) in the RAPS era. CSM at 6 years of follow‐up was 4.2% (95%CI: 3.8, 4.6) before and 4.8% (95%CI: 4.5, 5.1) in the RAPS era ( p = 0.002). In multivariable Cox models adjusted to patient characteristics, RAPS era did not predict higher CSM overall, in RP‐patients, or in RT‐patients (all p ≥ 0.5) aged ≥ 75 years. Limitations include changes in early detection and disease management over time, which might have impacted CSM as well.

Conclusions

The USPSTF RAPS introduction resulted in a 1.2‐fold higher CSM in localized PCa patients aged < 75 years, but not in patients aged ≥ 75 years. The time trend analysis suggested that this negative effect has become increasingly pronounced since the USPSTF RAPS.

Subjects

MeSH terms (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenEarly Detection of CancerHumansMaleAgedMiddle AgedSEER ProgramNeoplasm StagingUnited StatesPractice Guidelines as TopicProstatectomy

Author keywords

PSASEERmortalityprostate cancerradical prostatectomyscreening

Substances

Prostate-Specific Antigen

Authors and institutions

  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
  • Department of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.

ORCID profiles: Fabian Falkenbach, Jordan A Goyal

Funding

  • The authors received no specific funding for this work.

Cite

APA

Falkenbach, F., Di Bello, F., Peñaranda, N. R., Longoni, M., Marmiroli, A., Le, Q. C., Tian, Z., Goyal, J. A., Longo, N., Micali, S., Briganti, A., De Cobelli, O., Chun, F. K. H., Saad, F., Shariat, S. F., Budäus, L., Graefen, M., & Karakiewicz, P. I. (2025). USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70045

Vancouver

Falkenbach F, Di Bello F, Peñaranda NR, Longoni M, Marmiroli A, Le QC, et al. USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer. The Prostate. 2025. doi:10.1002/pros.70045

BibTeX
@article{Falkenbach2025,
  author = {Falkenbach, Fabian and Di Bello, Francesco and Peñaranda, Natali Rodriguez and Longoni, Mattia and Marmiroli, Andrea and Le, Quynh Chi and Tian, Zhe and Goyal, Jordan A and Longo, Nicola and Micali, Salvatore and Briganti, Alberto and De Cobelli, Ottavio and Chun, Felix K H and Saad, Fred and Shariat, Shahrokh F and Budäus, Lars and Graefen, Markus and Karakiewicz, Pierre I},
  title = {USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.70045}
}
Start for free →